Please use this identifier to cite or link to this item:
Title: The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib.
Issue Date: 2018
Citation: Br J Clin Pharmacol.2018 06;(84)6:1156-1169
Abstract: We investigated the effects of a strong CYP3A4 inhibitor (itraconazole) or inducer (rifampicin) on the pharmacokinetics of the epidermal growth factor receptor-tyrosine kinase inhibitor osimertinib, in patients with advanced non-small cell lung cancer in two Phase I, open-label, two-part clinical studies. Part one of both studies is reported.
PMID: 29381826
Rights: openAccess
Appears in Collections:Fundaciones e Institutos de Investigación > IIS H. U. La Paz > Artículos
Hospitales > H. U. La Paz > Artículos

Files in This Item:
File Description SizeFormat 
PMC5980546.pdf1.33 MBAdobe PDFThumbnail

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.